Tirzepatide & Hypercalcemia: A Case Report | Cureus

A new case report highlights a potential link between the diabetes drug tirzepatide and a dangerous rise in calcium levels, particularly in patients already taking thiazide diuretics like hydrochlorothiazide (HCTZ) and those with chronic kidney disease (CKD). The report, published in Cureus, details the case of a 65-year-old woman who developed severe hypercalcemia shortly after starting tirzepatide.

Hypercalcemia, an electrolyte disturbance characterized by abnormally high calcium levels in the blood, can cause a range of symptoms, including altered mental status, as experienced by the patient in this case. While commonly associated with conditions like primary hyperparathyroidism, cancer, or medication side effects, the connection to tirzepatide—a dual GIP and GLP-1 receptor agonist used for type 2 diabetes and obesity—has not been previously documented.

Tirzepatide and Calcium Levels: A Complex Interaction

The patient described in the report had a history of obesity, hypertension, stage 3 CKD, and type 2 diabetes. She was already being treated with hydrochlorothiazide (HCTZ) when tirzepatide was initiated. Shortly after starting the new medication, she presented with symptomatic hypercalcemia, with a corrected calcium level of 4.58 mmol/L, significantly above the normal range of 2.12-2.62 mmol/L. Further investigation ruled out malignancy and revealed low levels of parathyroid hormone (PTH) and vitamin D.

According to the case report, discontinuation of both tirzepatide and HCTZ, along with intravenous hydration and calcitonin administration, successfully normalized the patient’s calcium levels within four days of hospitalization. This rapid improvement suggests a strong association between the two medications and the hypercalcemia.

How Might Tirzepatide Affect Calcium?

The exact mechanism behind this potential interaction remains unclear, but researchers hypothesize that it involves a combination of factors. Thiazide diuretics are known to reduce urinary calcium excretion, leading to increased calcium reabsorption and potentially hypercalcemia. Tirzepatide, while typically considered to have minimal impact on calcium homeostasis, may influence bone turnover, further contributing to elevated calcium levels.

The report notes that GIP/GLP-1 agonists, the class of drugs to which tirzepatide belongs, generally do not significantly affect calcium levels. However, this case suggests that the combination with thiazide diuretics, particularly in individuals with pre-existing CKD, could create a unique scenario where hypercalcemia develops.

Implications for Patients and Clinicians

The authors of the case report emphasize the need for clinicians to be aware of the potential for severe hypercalcemia when prescribing tirzepatide to patients already taking thiazide diuretics, especially those with CKD. Close monitoring of calcium levels is recommended in these individuals.

Clinicians should be aware of the potential for severe hypercalcemia when tirzepatide is co-administered with chronic thiazide diuretics, particularly hydrochlorothiazide (HCTZ), in patients with pre-existing CKD.

Cureus case report authors

The report also calls for further research to better understand the interaction between tirzepatide and calcium metabolism. As the use of tirzepatide and other GLP-1/GIP agonists continues to increase for both diabetes and weight management, a clearer understanding of this potential side effect is crucial for ensuring patient safety.

While this case report represents only a single instance, it raises an important clinical consideration. The authors acknowledge that a single case cannot establish a definitive causal link, and further investigation is warranted to confirm these findings and determine the prevalence of this potential adverse effect.